The PALOMA‐2 trial showed that palbociclib plus letrozole can significantly improve PFS compared with placebo plus letrozole in the first‐line treatment of ER‐positive, HER2‐negative advanced breast cancer (median: 24.8 vs. 14.5 months) [69]. Here, ERBB2 is linked to breast cancer.